NAUT (CAMN107ADE22T) = Efficacy of nilotinib in inducing persistence of molecular remission after second or third TKI stop [Europe]

Study title

Efficacy of nilotinib in inducing persistence of molecular remission after second or third TKI stop

Scientific title

Multicenter prospective trial after first or second unsuccessful treatment discontinuation in chronic myeloid leukemia estimating the efficacy of nilotinib in inducing the persistence of molecular remission after stopping tyrosine kinase inhibitors a second or third time (ClinicalTrials.gov NCT02917720; EudraCT no. 2015-004998-33)

Type of study

Treatment discontinuation trial

Current status

No longer recruiting

What is the purpose of the study

Patients will be treated with nilotinib 600 mg/day for at least two years. Patients who achieve deep molecular remission (MR4.5 or better) at the end of treatment can attempt stopping TKI treatment.

The main objective of the study is to assess whether more patients maintain at least major molecular remission at 12 and 36 months after stopping TKI therapy.

Key inclusion criteria

This study includes patients from 18 years of age with chronic myeloid leukemia (CML) who have had a molecular relapse after a prior first or second attempt to stop therapy with a tyrosine kinase inhibitor (TKI) therapy and who have been treated for at least one year with any TKI after the first stop.

Key exclusion criteria

Where can I find additional information

Study sponsor

University of Heidelberg, Germany, with financial support from Novartis GmbH

Scientific lead / contact

Prof. Dr. Susanne Saußele
MCC-Studienzentrale, III. Med. Klinik
Medizinische Fakultät Mannheim der Universität Heidelberg
68167 Mannheim

Principal investigator

Prof. Dr. Susanne Saußele
MCC-Studienzentrale, III. Med. Klinik
Medizinische Fakultät Mannheim der Universität Heidelberg
68167 Mannheim

Study centers / principal investigators

Germany

Aachen
Universitätsklinikum der RWTH Aachen
Klinik für Hämatologie, Onkologie, Hämostaseologie und Stammzelltransplantation
Prof. Dr. med. Tim Henrik Brümmendorf
Pauwelsstr. 30
52074 Aachen

Bayreuth
Klinikum Bayreuth GmbH
Medizinische Klinik IV
PD Dr. med. Alexander Kiani
Preuschwitzer Str. 101
95445 Bayreuth

Chemnitz
Klinikum Chemnitz gGmbH
Klinik für innere Medizin III
Dr. med. Mathias Hänel
Flemmingstr. 2
09113 Chemnitz

Esslingen
Onkologische Schwerpunktpraxis
Dr. med. Robert Eckert
Berliner Str. 4
73728 Esslingen

Freiburg
Universitätsklinikum Freiburg
Innere Medizin I
Prof. Dr. Cornelius Waller
Hugstetter Str. 55
79108 Freiburg

Halle (Saale)
Universitätsklinikum Halle
Universitätsklinik und Poliklinik für Innere Medizin IV
PD Dr. med. Haifa Kathrin Al-Ali
Ernst-Grube-Str. 40
06120 Halle (Saale)

Hannover
Medizinische Hochschule Hannover
Klinik für Hämatologie, Hämostaseologie, Onkologie und Stammzelltransplantation
PD Dr. med. Christian Könecke
Carl-Neuberg-Str. 1
30625 Hannover

Heilbronn
Schwerpunktpraxis Onkologie
Dr. med. Jolanta Dengler
Allee 40
74072 Heilbronn

Mannheim
MCC-Studienzentrale, III. Med. Klinik
Medizinische Fakultät Mannheim der Universität Heidelberg
Prof. Dr. Susanne Saußele
68167 Mannheim

Marburg
Universitätsklinikum Gießen und Marburg,
Standort Marburg
Klinik für Hämatologie, Onkologie und Immunologi
Prof. Dr. med. Andreas Burchert
35043 Marburg

München
Klinikum rechts der Isar
Klinik und Poliklinik für innere Medizin III
Dr. med. Peter Herhaus
Ismaninger Str. 22
81675 München

Mutlangen
Klinikum Ostalb, Stauferklinikum Schwäbisch Gmünd
Zentrum für Innere Medizin
Prof. Dr. Holger Hebart
Wetzgauer Str. 85
73557 Mutlangen

Rostock
Universitätsmedizin Rostock
ZIM III – Hämatologie, Onkologie, Palliativmedizin
Prof. Dr. med. Christian Junghanß
Ernst-Heydemann-Straße 6
18057 Rostock

Villingen Schwenningen
Schwarzwald-Baar Klinikum
Klinik für Innere Medizin II
Prof. Dr. med. Paul Graf La Rosée
Klinikstraße 11
78052 Villingen-Schwenningen


The Netherlands

VU University Medical Center Amsterdam
Dr. Jeroen Janssen
1081 HV Amsterdam